Healthcare provider profile · identity verified

Arcangelo Distefano, MD

Internal Medicine · BRIDGEPORT, CT · NPI 1902869415

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	275	96
Atorvastatin Calcium	Atorvastatin Calcium	271	82
Furosemide	Furosemide	243	67
Levothyroxine Sodium	Levothyroxine Sodium	216	53
Pantoprazole Sodium	Pantoprazole Sodium	173	54
Eliquis	Apixaban	158	13
Lisinopril	Lisinopril	147	58
Gabapentin	Gabapentin	145	37
Glipizide Er	Glipizide	140	44
Losartan Potassium	Losartan Potassium	110	50
Sertraline Hcl	Sertraline Hcl	110	21
Metformin Hcl	Metformin Hcl	108	36
Hydrochlorothiazide	Hydrochlorothiazide	106	36
Omeprazole	Omeprazole	103	35
Meloxicam	Meloxicam	89	35
Rosuvastatin Calcium	Rosuvastatin Calcium	84	32
Metoprolol Succinate	Metoprolol Succinate	83	26
Pravastatin Sodium	Pravastatin Sodium	83	30
Albuterol Sulfate Hfa	Albuterol Sulfate	81	27
Zolpidem Tartrate	Zolpidem Tartrate	81	27
Metoprolol Tartrate	Metoprolol Tartrate	78	20
Januvia	Sitagliptin Phosphate	76	22
Carvedilol	Carvedilol	74	21
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	73	64
Lorazepam	Lorazepam	71	28
Allopurinol	Allopurinol	66	17
Clopidogrel	Clopidogrel Bisulfate	64	14
Simvastatin	Simvastatin	56	19
Duloxetine Hcl	Duloxetine Hcl	55	suppressed
Alprazolam	Alprazolam	54	19
Baclofen	Baclofen	54	26
Ciprofloxacin Hcl	Ciprofloxacin Hcl	53	50
Entresto	Sacubitril/Valsartan	52	suppressed
Fluticasone Propionate	Fluticasone Propionate	50	19
Escitalopram Oxalate	Escitalopram Oxalate	49	19
Amoxicillin	Amoxicillin	44	36
Mirtazapine	Mirtazapine	41	14
Naproxen	Naproxen	40	15
Spironolactone	Spironolactone	40	suppressed
Diazepam	Diazepam	39	15
Meclizine Hcl	Meclizine Hcl	39	24
Donepezil Hcl	Donepezil Hcl	38	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	38	suppressed
Mometasone Furoate	Mometasone Furoate	36	18
Clonazepam	Clonazepam	34	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	34	suppressed
Jardiance	Empagliflozin	32	suppressed
Ketoconazole	Ketoconazole	32	17
Potassium Chloride	Potassium Chloride	32	14
Tamsulosin Hcl	Tamsulosin Hcl	32	13
Tradjenta	Linagliptin	32	suppressed
Hydralazine Hcl	Hydralazine Hcl	29	suppressed
Levetiracetam	Levetiracetam	29	suppressed
Valsartan	Valsartan	29	suppressed
Linzess	Linaclotide	28	suppressed
Metformin Hcl Er	Metformin Hcl	27	11
Quetiapine Fumarate	Quetiapine Fumarate	27	suppressed
Trazodone Hcl	Trazodone Hcl	27	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	24	suppressed
Memantine Hcl	Memantine Hcl	24	suppressed
Ondansetron Hcl	Ondansetron Hcl	24	suppressed
Prednisone	Prednisone	24	11
Alendronate Sodium	Alendronate Sodium	23	suppressed
Topiramate	Topiramate	23	suppressed
Tramadol Hcl	Tramadol Hcl	23	13
Azithromycin	Azithromycin	22	20
Colchicine	Colchicine	21	suppressed
Diclofenac Sodium	Diclofenac Sodium	21	suppressed
Flecainide Acetate	Flecainide Acetate	21	suppressed
Myrbetriq	Mirabegron	21	suppressed
Ventolin Hfa	Albuterol Sulfate	21	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	19	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Methylprednisolone	Methylprednisolone	19	18
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	19	suppressed
Warfarin Sodium	Warfarin Sodium	19	suppressed
Atenolol	Atenolol	18	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	18	suppressed
Lurasidone Hcl	Lurasidone Hcl	18	suppressed
Nystatin	Nystatin	18	suppressed
Ondansetron Odt	Ondansetron	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Labetalol Hcl	Labetalol Hcl	16	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	16	suppressed
Buspirone Hcl	Buspirone Hcl	15	suppressed
Montelukast Sodium	Montelukast Sodium	15	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Citalopram Hbr	Citalopram Hydrobromide	14	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	14	suppressed
Brimonidine Tartrate-Timolol	Brimonidine Tartrate/Timolol	13	suppressed
Ezetimibe	Ezetimibe	13	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Neomycin-Polymyxin-Hydrocort	Neomycin/Polymyxin B/Hydrocort	13	13
Penicillin V Potassium	Penicillin V Potassium	13	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Nebivolol Hcl	Nebivolol Hcl	12	suppressed
Ozempic	Semaglutide	12	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	12	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error